Filing Flows › ARS Pharmaceuticals (SPRY) › Revenue Under Supply Agreements revenue
ARS Pharmaceuticals (SPRY) Revenue Under Supply Agreements revenue by quarter
ARS Pharmaceuticals' Revenue Under Supply Agreements revenue was $2.6M in Q3 2026 (third quarter 2026), -64% from Q2 2026. Over the last 6 quarters it ranged from $323K (Q2 2025) to $7.4M (Q2 2026).
| Quarter | Revenue Under Supply Agreements revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.6M | -64% | +130% |
| Q2 2026 | $7.4M | +170% | 23× |
| Q1 2026 | $2.7M | +204% | — |
| Q4 2025 | $901K | -21% | — |
| Q3 2025 | $1.1M | +255% | — |
| Q2 2025 | $323K | — | — |
Q3 2026 at a glance
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is ARS Pharmaceuticals' Revenue Under Supply Agreements revenue?
ARS Pharmaceuticals' Revenue Under Supply Agreements revenue was $2.6M in Q3 2026 (third quarter 2026), -64% from Q2 2026.
How has ARS Pharmaceuticals' Revenue Under Supply Agreements revenue changed?
Over the last 6 quarters it ranged from $323K (Q2 2025) to $7.4M (Q2 2026).